CRISPR is no longer a promise. It’s an approved medicine. Here’s the real-world scoreboard of what gene editing has achieved against some of humanity’s most stubborn diseases.
The first CRISPR medicine is already saving lives
In December 2023, the FDA approved Casgevy — the first CRISPR-based medicine ever authorized for human use. It treats sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), two inherited blood disorders that affect millions of people worldwide and were previously managed, but not cured. Casgevy changes that.
The therapy works by editing a patient’s own blood stem cells outside the body. Using CRISPR, it reactivates a fetal hemoglobin gene that the body normally switches off after birth — restoring healthy red blood cell function. The results from clinical trials are striking: 94% of treated sickle cell patients achieved freedom from vaso-occlusive crises — the excruciating pain episodes that define the disease — for at least one year. Since approval, 50 active treatment sites across North America, Europe, and the Middle East have opened and begun treating patients.
📊 Clinical results: 94% of sickle cell patients treated with Casgevy had no vaso-occlusive crises for at least 12 months. For a disease that had no cure for over a century, this is a profound result.
CRISPR takes on heart disease — and wins the first round
In November 2025, results from a phase 1 clinical trial presented at the American Heart Association’s Scientific Sessions made headlines. A single one-time CRISPR therapy safely reduced LDL cholesterol and triglycerides in 15 patients with difficult-to-treat lipid disorders. The treatment targets the PCSK9 gene — permanently silencing it in liver cells, eliminating the need for lifelong medication.
This is significant not just for cardiology, but for the broader concept of CRISPR medicine. Most of the drugs we take for chronic conditions — statins, blood pressure medications — require daily adherence for decades. A single CRISPR treatment that permanently corrects the underlying biology could replace years of pills, improving outcomes and reducing the burden on patients and healthcare systems alike.
CRISPR vs. HIV: Still fighting, but making real progress
HIV remains one of medicine’s hardest problems because the virus hides its DNA inside the patient’s own cells — where antiretroviral drugs can suppress it but never fully eliminate it. CRISPR offers a different approach: go find the hidden viral DNA and cut it out of the genome permanently.
Excision Biotherapeutics has completed a phase I/II trial of exactly this approach. Their CRISPR therapy uses guide RNAs to target two specific sites within the HIV genome embedded in patient cells, with Cas9 cutting at both points to surgically excise the viral DNA. The treatment is delivered by an AAV9 viral vector in a single IV infusion. The phase I results established safety. The bigger efficacy questions will be answered in the next trial phase — but the direction is clear.
Separately, a 2025 study from the Ragon Institute at Harvard, MIT, and Mass General used CRISPR to edit the CCR5 gene — the main receptor HIV uses to enter cells — in over 90% of human blood stem cells, with minimal detectable off-target effects. This could render cells resistant to HIV infection entirely, representing a fundamentally different approach to a functional cure.
🔬 Also in the pipeline: CRISPR trials are now active or in development for: cancer (multiple types), Alzheimer’s disease, ALS, Huntington’s disease, hereditary blindness (Leber Congenital Amaurosis), hereditary angioedema, and antibiotic-resistant bacterial infections.